In vivo pharmacodynamic studies showed that LXI-15029 had a selective antitumor activity in human renal carcinoma, gastric cancer, breast cancer, and lung cancer with abnormal regulation in the mTOR signaling pathway in nude mouse xenograft models [25, 26]. The gene discussed is MTOR; the disease is breast carcinoma.